EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. increased its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 92.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 3,707,445 shares of the company’s stock after buying an additional 1,783,765 shares during the quarter. Federated Hermes Inc. owned about 0.05% of EyePoint Pharmaceuticals worth $27,620,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EYPT. KLP Kapitalforvaltning AS bought a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter worth about $59,000. AlphaQuest LLC raised its holdings in EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock worth $73,000 after purchasing an additional 9,670 shares in the last quarter. Raymond James Financial Inc. bought a new stake in EyePoint Pharmaceuticals during the fourth quarter worth approximately $76,000. China Universal Asset Management Co. Ltd. lifted its position in EyePoint Pharmaceuticals by 40.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock worth $108,000 after purchasing an additional 4,179 shares during the period. Finally, Teacher Retirement System of Texas boosted its stake in EyePoint Pharmaceuticals by 22.4% during the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company’s stock valued at $113,000 after purchasing an additional 2,782 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Trading Down 10.6 %

EYPT stock opened at $4.13 on Wednesday. EyePoint Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $23.65. The firm has a 50-day moving average of $6.26 and a two-hundred day moving average of $8.00. The firm has a market capitalization of $283.85 million, a PE ratio of -2.07 and a beta of 1.39.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $11.02 million. On average, equities research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on EYPT. Chardan Capital reissued a “buy” rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday, March 14th. Finally, Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price on the stock. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to MarketBeat, EyePoint Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.